SARKKOS Therapeutics is advancing a small-molecule discovery program that progresses to the hit discovery phase for our specific target. SARKKOS Therapeutics aims to identify promising hits using high-throughput and computational screening. Those hits will be identified and confirmed against validated disease targets. In parallel, the team will integrate in vitro assays to understand the mechanism of action of our target, and early in vivo models to assess biological activity and safety to select high-quality lead candidates.